These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25514543)

  • 1. Treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol.
    Hässler F; Dück A; Jung M; Reis O
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):579-81. PubMed ID: 25514543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study.
    Haessler F; Glaser T; Beneke M; Pap AF; Bodenschatz R; Reis O;
    Br J Psychiatry; 2007 May; 190():447-8. PubMed ID: 17470962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation--a 2-year follow-up on a withdrawal study.
    Hässler F; Glaser T; Reis O
    Pharmacopsychiatry; 2011 Nov; 44(7):339-43. PubMed ID: 21993867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study.
    Spivak B; Mozes T; Mester R; Kodelik M; Weizman A
    J Child Adolesc Psychopharmacol; 2001; 11(3):279-84. PubMed ID: 11642477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour.
    Schwarz V; Reis O; Glaser T; Thome J; Hiemke C; Haessler F
    Pharmacopsychiatry; 2014 Jan; 47(1):29-32. PubMed ID: 24307207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.
    Hässler F; Glaser T; Pap AF; Beneke M; Diefenbacher A; Reis O;
    Pharmacopsychiatry; 2008 Nov; 41(6):232-9. PubMed ID: 19067260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.
    Fuglum E; Schillinger A; Andersen JB; Belstad BE; Jensen D; Müller F; Müller KJ; Schulstad B; Elgen K
    Pharmatherapeutica; 1989; 5(5):285-91. PubMed ID: 2568639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders.
    Singh I; Owino WJ
    J Intellect Disabil Res; 1992 Dec; 36 ( Pt 6)():541-9. PubMed ID: 1477491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients.
    Izmeth MG; Khan SY; Kumarajeewa DI; Shivanathan S; Veall RM; Wiley YV
    Pharmatherapeutica; 1988; 5(4):217-27. PubMed ID: 2902642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
    Hovens JE; Dries PJ; Melman CT; Wapenaar RJ; Loonen AJ
    J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study.
    Nygaard H; Bakke K; Brudvik E; Lien GK; Moe TJ; Elgen K
    Pharmatherapeutica; 1988; 5(3):152-8. PubMed ID: 2896359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder.
    Carminati GG; Gerber F; Darbellay B; Kosel MM; Deriaz N; Chabert J; Fathi M; Bertschy G; Ferrero F; Carminati F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():85-95. PubMed ID: 26361994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients.
    Malt UF; Nystad R; Bache T; Noren O; Sjaastad M; Solberg KO; Tønseth S; Zachariassen P; Maehlum E
    Br J Psychiatry; 1995 Mar; 166(3):374-7. PubMed ID: 7788130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zuclopenthixol, melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway.
    Nygaard HA; Fuglum E; Elgen K
    Curr Med Res Opin; 1992; 12(10):615-22. PubMed ID: 1353014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.
    Buitelaar JK
    J Child Adolesc Psychopharmacol; 2000; 10(1):19-26. PubMed ID: 10755578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy.
    Rubio-Gozalbo ME; van Waardenburg DA; Forget PP; Spaapen LJ; Verrips A; Vroomen PC
    J Inherit Metab Dis; 2001 Oct; 24(5):605-6. PubMed ID: 11757591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
    Deb S; Unwin G; Deb T
    J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of zuclopenthixol in the treatment of aggression in Huntington's disease.
    Tibrewal P; Bastiampillai T; Dhillon R; Cheng R; Fonseka HT
    Asian J Psychiatr; 2017 Apr; 26():152-153. PubMed ID: 28483083
    [No Abstract]   [Full Text] [Related]  

  • 20. Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
    Bobon D; Troisfontaines B; Kempeneers JL; Xhenseval B; Bourdouxhe S; Mirel J; Gilson H; Toussaint C; von Frenckell R; Pedersen V
    Acta Psychiatr Belg; 1986; 86(2):152-76. PubMed ID: 2873713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.